telavancin hydrochloride · Apotex · NDA 022110
Vibativ
Earliest generic entry, as listed
1 Jan 2027
Blocked by patent: US 7531623.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7531623 | drug substance · sets the listed date | 1 Jan 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 022110-002Listed date 1 Jan 2027Detected 24 Oct 2026
- Enters 12-month window basis: patent · 022110-001Listed date 1 Jan 2027Detected 24 Oct 2026
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022110 · 001 · RLD · discontinued | powder, intravenous | EQ 250MG BASE/VIAL | 1 Jan 2027 |
| 022110 · 002 · RLD | powder, intravenous | EQ 750MG BASE/VIAL | 1 Jan 2027 |